共 190 条
[1]
Haugen BR(2016)2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid 26 1-133
[2]
Alexander EK(2002)Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma Thyroid 12 121-134
[3]
Bible KC(1962)The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer Am J Roentgenol Radium Therapy Nucl Med 87 171-182
[4]
Doherty GM(2003)Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach J Nucl Med 44 451-456
[5]
Mandel SJ(2009)Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma Thyroid 19 1093-1098
[6]
Nikiforov YE(1976)In vivo quantitation of lesion radioactivity using external counting methods Med Phys 3 253-255
[7]
Van Nostrand D(2011)The use of dosimetry in the treatment of differentiated thyroid cancer Q J Nucl Med Mol Imaging 55 107-115
[8]
Atkins F(2009)124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison J Nucl Med 50 1844-1847
[9]
Yeganeh F(2010)131I-tositumomab radioimmunotherapy: Initial tumor dose–response results using 3-dimensional dosimetry including radiobiologic modeling J Nucl Med 51 1155-1162
[10]
Acio E(1983)Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer New Engl J Med 309 937-941